The French laboratory Sanofi published on Monday positive results of a clinical trial on its main candidate vaccine against Covid-19, developed with the British GSK, after a setback that had caused several months of delay.
Read also: Flu shots carry Sanofi
The interim results of this phase 2 human trial show that administration of this vaccine "
induced the production of high concentrations of neutralizing antibodies in adults of all age groups at levels comparable to those observed in people who had recovered from an infection
”Covid, details the laboratory in a press release on Monday.
/cloudfront-eu-central-1.images.arcpublishing.com/prisa/H7U7FJNUZBG6BPL5PZCMGC6EUY.jpg)